Nickel Cerstin, Tritt Karin, Muehlbacher Moritz, Pedrosa Gil Francisco, Mitterlehner Ferdinand O, Kaplan Patrick, Lahmann Claas, Leiberich Peter K, Krawczyk Jakub, Kettler Christian, Rother Wolfhardt K, Loew Thomas H, Nickel Marius K
Clinic for Psychosomatic Medicine, Inntalklinik, Simbach am Inn, Germany.
Int J Eat Disord. 2005 Dec;38(4):295-300. doi: 10.1002/eat.20202.
The aim of the current study was to test the influence of topiramate on behavior, body weight, and health-related quality of life (HRQOL) in bulimic patients.
Thirty patients with bulimia nervosa were treated with topiramate in a 10-week randomized, double-blind, placebo-controlled study. The subjects were randomly assigned to receive topiramate (topiramate group [TG]; n = 30) or a placebo (control group [CG]; n = 30). Primary outcome measures were changes in the frequency of binging/purging, in body weight, and on the SF-36 Health Survey (SF-36) scales.
In comparison to the CG group (according to the intent-to-treat principle), significant changes in the frequency of binging/purging (a > 50% reduction: TG, n = 11 [36.7%]; CG, n = 1 [3.3%]; p < .001), body weight (difference in weight loss between the two groups: 3.8 kg, 95% confidence interval [CI] = -5.4 to -2.1; p < .001), and SF-36 (all ps < .001) could be seen. All patients tolerated topiramate well.
Topiramate appears to safe and effective in influencing the frequency of binging/purging, body weight, and HRQOL in bulimic patients.
本研究旨在测试托吡酯对贪食症患者的行为、体重及健康相关生活质量（HRQOL）的影响。
在一项为期10周的随机、双盲、安慰剂对照研究中，30例神经性贪食症患者接受了托吡酯治疗。受试者被随机分配接受托吡酯（托吡酯组[TG]；n = 30）或安慰剂（对照组[CG]；n = 30）。主要结局指标为暴饮暴食/催吐频率、体重及SF-36健康调查量表的变化。
与CG组相比（根据意向性分析原则），在暴饮暴食/催吐频率（减少>50%：TG组，n = 11[36.7%]；CG组，n = 1[3.3%]；p <.001）、体重（两组体重减轻差异：3.8 kg，95%置信区间[CI] = -5.4至-2.1；p <.001）和SF-36量表（所有p值<.001）方面均有显著变化。所有患者对托吡酯耐受性良好。
托吡酯在影响贪食症患者的暴饮暴食/催吐频率、体重及健康相关生活质量方面似乎安全有效。
Zotero 插件